BeOne Medicines (ONC) Interest & Investment Income (2015 - 2026)

BeOne Medicines' (ONC) quarterly Interest & Investment Income came in at $27.7 million in Q1 2026, up 115.28% year-on-year from $12.8 million in Q1 2025, and up 115.28% on a QoQ basis from $12.8 million in Q1 2025.

BeOne Medicines (ONC) Interest & Investment Income (2015 - 2026) Analysis & Trends

BeOne Medicines (ONC) has 4 years of Interest & Investment Income data on file, last reported at $27.7 million in Q1 2026.

  • On a quarterly basis, Interest & Investment Income rose 115.28% year-over-year to $27.7 million in Q1 2026; TTM through Mar 2026 was $41.0 million, a 196.67% increase from a year earlier, with the FY2025 full-year figure at $70.5 million, up 1.24% from the prior year.
  • Interest & Investment Income for Q1 2026 stood at $27.7 million, up from $12.8 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for ONC reached as high as $27.7 million in Q1 2026 and fell as low as $12.8 million in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 27.66 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 114.80 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -65.80 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 48.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - 19.51 Mn
10 Alnylam Pharmaceuticals 37.29 Bn 34.28 Bn 959.66 Mn 26.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 27.66 Mn
Mar 31, 2025 12.85 Mn
Sep 30, 2016 209,000.00
Jun 30, 2016 262,000.00
Mar 31, 2016 494,000.00
Sep 30, 2015 760,000.00
Jun 30, 2015 409,000.00
Mar 31, 2015 117,000.00